mergers
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Healthcare M&A and IRA Price Negotiations: Key Trends to Watch Amidst Political Shifts
Healthcare M&A, IRA Price Negotiations, Medicare Drug Price Negotiation Program, Inflation Reduction Act, Pharmaceutical Industry Trends, Mergers and Acquisitions Outlook 2024
Insights from Jade CEO: Reverse Merger and IgAN Drug Development
Jade CEO, Reverse Merger, IgAN Drugs, Pharmaceutical Development, Biotech Mergers
Roche CEO Urges Antitrust Regulators to Block Novo Holdings’ Acquisition of Catalent
Novo Holdings, Catalent, Roche, Antitrust Regulators, Pharmaceutical Industry, Mergers and Acquisitions
TRACON Pharmaceuticals Discontinues Envafolimab Development, Explores Strategic Options
TRACON Pharmaceuticals, Envafolimab, Oncology, Clinical Trial, Strategic Options, Mergers, Acquisitions, Asset Sales
Pfizer, Bristol Myers Squibb, and Johnson & Johnson: Navigating the Looming Patent Cliff
Patent Cliff, Pharmaceutical Industry, Pfizer, Bristol Myers Squibb, Johnson & Johnson, Patent Expirations, Biologics, Biosimilars, Revenue Loss, Mergers and Acquisitions
BMS Realigns Workforce Post-Mergers and Acquisitions: A Strategic Move Affecting 2,200 Employees
BMS, layoffs, mergers and acquisitions, workforce realignment, strategic move, 2, 200 employees
Novartis Appoints Ex-Bristol Myers CEO Giovanni Caforio as Chair: Potential for Future M&A Deals?
Novartis, Bristol Myers, Giovanni Caforio, Chair, Mergers and Acquisitions (M&A), Pharmaceutical Industry, Corporate Strategy, Leadership Change.